Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alvaro Ortega-Carrion"'
Autor:
Jose Maria Portoles, Carlos Jimenez, Dario Janeiro, Maria O. Lopez-Oliva, Alvaro Ortega-Carrion, Daniel Blanquez, Luis Arribas, Carlos Gomez, Teresa Diez, Julio Pascual, Isabel Portero
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Immunosuppressive drugs are widely used to treat several autoimmune disorders and prevent rejection after organ transplantation. However, intra-individual variations in the pharmacological response to immunosuppressive therapy critically influence it
Externí odkaz:
https://doaj.org/article/3bc5736d6a1b484ca6c8e5e858a3be3a
Publikováno v:
F1000Research, Vol 5 (2016)
The term “immune synapse” was originally coined to highlight the similarities between the synaptic contacts between neurons in the central nervous system and the cognate, antigen-dependent interactions between T cells and antigen-presenting cells
Externí odkaz:
https://doaj.org/article/db85a2260caf4b98ba9bdf452c29dd64
Autor:
Julio Pascual, Marta Crespo, Jose Portoles, Carlos Jimenez, Alvaro Ortega-Carrion, Teresa Diez, Isabel Portero
Publikováno v:
International Journal of Molecular Sciences. 24:5201
Immunosuppressive drugs are widely used to prevent rejection after kidney transplantation. However, the pharmacological response to a given immunosuppressant can vary markedly between individuals, with some showing poor treatment responses and/or exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bb34acb4105b97fcb0c4cf4483f2f75
https://doi.org/10.3390/ijms24065201
https://doi.org/10.3390/ijms24065201
Autor:
Miguel Vicente-Manzanares, Oscar Brück, Satu Mustjoki, Alba Juanes-García, Jani Saarela, Alvaro Ortega-Carrion, Yaiza Pérez-García, Beatriz Colom-Fernández, Cecilia Muñoz-Calleja, Carlos Cuesta-Mateos, Anna Kreutzman, Ana Marcos Jiménez, Juan Luis Steegmann, Cristina Delgado Arévalo, Ana de Rosendo, Mette Ilander
Publikováno v:
IBJ Plus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0a2e26c3e5eecd5bdbf8a8fa270c06
https://doi.org/10.24217/2531-0151.18v1s1.00009
https://doi.org/10.24217/2531-0151.18v1s1.00009
Autor:
Ana Marcos Jiménez, Juan Luis Steegmann, Beatriz Colom-Fernández, Alba Juanes-García, Ana de Rosendo, Mette Ilander, Jani Saarela, Alvaro Ortega-Carrion, Anna Kreutzman, Yaiza Pérez-García, Cecilia Muñoz-Calleja, Carlos Cuesta-Mateos, Cristina Delgado Arévalo, Oscar Brück, Satu Mustjoki, Henna Hakanen, Miguel Vicente-Manzanares
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Purpose]: Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very effective, patients taking dasatinib often display severe adverse effects, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea6f5b2dfb4d136bcaa94218a5ab0c2
https://pubmed.ncbi.nlm.nih.gov/28821556
https://pubmed.ncbi.nlm.nih.gov/28821556